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Abstract
Despite continuous improvements in treating clinical symptoms and the identification of single compounds that
effectively rescue some rare mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), associated
lung and liver pathologies remain largely untreatable and no real breakthrough is visible for the majority of patients
suffering from cystic fibrosis (CF).
Novel compounds have to be identified and tailored in combination to specific CFTR mutations, to different tissues, or
even to the individual patient. Immortalized cell lines overexpressing mutant CFTR are typically used to screen candidate
molecules but have proven to be poor predictors of clinical efficacy. The complexity of CFTR maturation and turnover
requires the use of cellular models that closely recapitulate the specific properties of the clinically most affected organs.
Importantly, current screening efforts based on primary airway cells or intestinal organoids cannot specifically target
single rare CFTR mutations or mimic multiple cell types.
In the near future, genetically engineered induced pluripotent stem cells will provide an excellent basis for
personalized organotypic models of CF disease and biological screens for identification of CFTR potentiators
and correctors.
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Background
Regardless of substantial clinical progress, cystic fibrosis
(CF) is still a fatal congenital disease, affecting more
than 70,000 patients worldwide, with high morbidity and
a limited lifespan. Health care costs are estimated to be
3–4 billion € per year. Despite decades of intense re-
search, gene therapy of CF did not enter clinical routine.
Low transduction efficiencies in airway cells, immune re-
actions, and failure to achieve long-term expression in
vivo prevented broader clinical application. Importantly,
although the recent identification of cystic fibrosis trans-
membrane conductance regulator (CFTR) correctors
and potentiators is promising, no compounds are avail-
able thus far which show significant clinical benefit in all
F508del-carrying patients. In the case of other, more rare
but substantial trafficking defect mutations (http://
www.cftr2.org), which also cause severe CF lung pancre-
atic and liver involvement, existing correctors have not
yet been shown to be effective. Thus, novel therapeutic
concepts, as well as correctors showing clinical benefit
and leading to a normal lifespan and the capacity to par-
ticipate in social and economic life for patients carrying
such mutations would entail substantial benefit for the
community as a whole.
Is there a need for stem cell-based drug
screening?
Nearly 2000 CFTR gene mutations are known, of
which ~130 are pathogenic, impairing its translation, cel-
lular processing, and/or chloride channel gating. There-
fore, small molecule therapy restoring function to mutant
CFTR is a priority in the field. High throughput (HT)
screens have identified CFTR potentiators, which restore
the channel activity by enhancing gating [1, 2], and correc-
tors, which rescue the most frequent trafficking mutant
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(F508del) to the cell surface in vitro. The potentiator Iva-
caftor (VX-770) was approved by US Food and Drug Ad-
ministration/European Medicines Agency (FDA/EMA) in
2013 for G551D and recently for further eight gating mu-
tations. However, these mutations are present in just 4–
5 % of all CF patients. For most CF patients, an effective
small molecule treatment is not yet available. Thus far, re-
sults from clinical trials on patients homozygous for
F508del with the best known corrector drugs (VX-809/
661) are modest [3]. A combination of the correctors VX-
809/661 and the potentiator VX-770 did improve lung
function but only to a limited extent (~4 %) [4, 5] and re-
portedly only in a subgroup of patients [6]. Moreover, only
~40 % of patients are F508del homozygous and the effi-
cacy of correctors for patients with only one F508del allele
is expected to be even lower. At least 15 % of all CF pa-
tients are unlikely to benefit from F508del-CFTR cor-
rector therapies, as they lack F508del in both alleles.
It is therefore clear that in the case of F508del and
other trafficking mutations, novel compounds have to be
identified. Indeed, current data indicate that a combin-
ation of CFTR correctors, potentiators, and molecules
that prevent an excessive turnover of mutant proteins
will be required [7]. This combination ideally should be
tailored not only to specific CFTR mutations but also to
the individual patient, who in most cases presents two
different mutations. Furthermore, the complexity of the
mutant CFTR maturation and turnover kinetics requires
the use of advanced cellular models that closely recap-
itulate the properties of the most affected organs (lung,
bile duct, pancreas, and intestine). Ideally, this should be
implemented at the screening stage to rapidly filter out
compounds that are ineffective or toxic to the human
native epithelium. However, primary culture techniques
are cumbersome and, despite recent progress [8], airway
cells of rare mutants, which are usually available only
through bronchial brushes, will probably not provide
enough material for HT assays. Also, it has to be empha-
sized that current large screening initiatives based on
primary airway cells are not able to target rare CF muta-
tions, since explanted lung tissue homozygous for rare
mutations is generally not available. Furthermore, the
genetic engineering of differentiated primary cells to es-
tablish appropriate reporter lines is extremely difficult.
Most screens have therefore been performed using im-
mortalized cell lines overexpressing CFTR mutants and
halide indicators [9]. Only the most promising com-
pounds were validated on primary human bronchial epi-
thelial cells and showed highly variable and limited
correction. However, the validation of compounds in
stable organotypic cell systems at an early stage is essen-
tial, as immortalized cell lines do not show the physio-
logical characteristics of the relevant respiratory,
intestinal, pancreatic, or bile duct epithelia, including
regulation of CFTR expression, traffic, and function, in
particular in the context of inflammation and tissue in-
jury responses.
It is therefore not surprising that immortalized cell
lines overexpressing mutant CFTR variants are poor pre-
dictors of clinical efficacy and that alternative screening
methods are required. It is consensus that those HT and
medium throughput (MT) assays which have been used
for identification of existing potentiators and modulators
are suboptimal, in particular because all of them relied
on immortalized cell lines overexpressing mutant CFTR
variants without considering the patient’s genomic back-
ground and specific cellular and molecular characteris-
tics of primary airway and bile duct epithelium.
Addressing at least some of these limitations, a method
to propagate intestinal organoids from individual CF pa-
tients was recently developed, which is now used as a
novel, individualized screening platform for small mole-
cules [10]. Certainly this represents a major step forward,
and intestinal organoids grown from gut biopsies appar-
ently closely reflect the properties of CF disease intestinal
epithelium. On the other hand, it has not yet been firmly
shown that intestinal organoids directly recapitulate the
functional characteristics of diseased airway epithelium
and that CFTR activity in these organoids is an accurate
predictor of CF lung disease, the most serious cause of
morbidity and mortality in CF. Notably, also progressive
pancreas and liver pathology caused by the plugging of
pancreatic and biliary ducts present serious and frequent
complications, which are untreatable using currently avail-
able interventions [11]. Clearly, it is not obvious that com-
pounds validated in the intestinal model, which presents
only partially differentiated enterocytes, will cover all as-
pects of CFTR trafficking correction.
Induced pluripotent stem cells for drug screening
and disease modeling
Until recently, screening activities aiming at the identifica-
tion of novel correctors and potentiators were hampered by
the lack of a suitable source of expandable patient-derived
cells that can be easily genetically engineered. These limita-
tions were recently overcome by two groundbreaking devel-
opments: In 2006, Yamanaka demonstrated the possibility to
reprogram somatic cells into the so-called induced pluripo-
tent stem cells (iPSCs) [12], a finding that was awarded the
Nobel Prize in Medicine in 2012. And probably as import-
ant, novel technologies for efficient targeted genome engin-
eering using designer nucleases such as Transcription
Activator-like Effector Nucleases (TALENs) or the Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR)
system opened the opportunity for specific correction and
introduction of mutations as well as efficient targeted inser-
tion of transgenes [13].
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Meanwhile, the generation of human iPSCs has be-
come a standard procedure in many laboratories and it
is now clear that these cells are almost indistinguishable
from embryonic stem cells (ESCs) with respect to their
phenotype, culture characteristics, and potential for pro-
liferation and differentiation [14]. Remarkably, low re-
programming efficiencies are not critical anymore with
reported efficiencies of up to 100 % [15]. In addition, re-
programming of a variety of cell types was demon-
strated. Whereas invasive skin biopsies for isolation of
fibroblasts were initially required, nowadays iPSCs can
be isolated from hair bulks or blood as easily accessible
cell sources [16–18].
From a practical standpoint and industrial perspective, it
was mandatory to address further issues that are critical for
large-scale application of iPSC derivatives in drug screening
and safety pharmacology. This includes the hitherto inabil-
ity to produce large cell masses of iPSC in defined culture
media. As for reprogramming efficiencies, major progress
could be achieved also in this field and our group was able
to demonstrate the possibility of long-term expansion of
human-induced pluripotent stem cells in scalable suspen-
sion culture under defined conditions [19, 20]. Meanwhile,
large numbers of human iPSCs can be produced in fully
controlled stirred bioreactors [21].
The lack of robust and efficient differentiation protocols
enabling the directed derivation of specific cell lineages has
been another limiting factor for the development of stem
cell-based therapies. However, sequential inhibition and ac-
tivation of molecular differentiation pathways now allow a
targeted and efficient differentiation of human pluripotent
stem cells into various lineages. Of special relevance for CF,
hiPSC-derived bile duct epithelium can be obtained if suit-
able differentiation protocols are applied [22]. Also, remark-
able progress was achieved during recent years concerning
the differentiation of pulmonary cells. As a prerequisite for
generation of mature airway cells, efficient derivation of de-
finitive endoderm and anterior foregut endoderm from
murine and human pluripotent stem cells was achieved
through initial activation of nodal signaling by Activin A
and subsequent dual inhibition of transforming growth fac-
tor (TGF)-β and bone morphogenic protein (BMP) signal-
ing applying the chemical compounds dorsomorphin,
IWP2, and SB431542 [23–25]. Subsequent treatment with
Wnt3a or CHIR, a chemical Wnt-agonist, fibroblast growth
factor 10 and bone morphogenetic protein 4 led to ventrali-
zation and targeted generation of early lung progenitors
[24, 26, 27]. Also, key factors for further specification of dif-
ferent respiratory lineages including keratinocyte growth
factor, dexamethasone, and cAMP-elevating agents were
identified [24, 26–29]. It is noteworthy that small organic
molecules as a cheap alternative with fewer lot-to-lot varia-
tions are increasingly replacing recombinant proteins in
such protocols [30]. In case of cardiomyocytes, our group
already succeeded in the development of highly efficient,
scalable protocols that are exclusively based on chemical
compounds and thus are relatively inexpensive and robust
and result in dramatically improved cardiac differentiation
efficiencies of up to 95 % in fully controllable stirred bio-
reactor systems [31], enabling the production of the vast
numbers of cardiomyocytes required for drug screening
and clinical cell therapy. However, respiratory differenti-
ation protocols are more complex and as yet replacement
of recombinant proteins could be achieved only partially.
In contrast to primary bronchial cells, which presently
provide the standard in differentiated airway cell culture,
iPSCs show an unlimited potential for proliferation and
differentiation. Also of relevance in particular for auto-
mated high throughput drug screening is the possibility to
apply novel site-specific gene editing in hiPSCs including
TALENs [13]. This opens up the unique possibility to gen-
erate patient and CFTR mutation-specific cell lineages, car-
rying halide- or voltage-sensitive fluorescent proteins for
functional screens or reporter tags within the endogenous
CFTR gene for direct visualization of trafficking. Clearly,
such opportunities will constitute an important step to run
high throughput screening of chemical libraries.
Remarkably, while gene editing in intestinal organoids
that are generated based on patient-specific intestinal
stem cells from gut biopsies currently requires antibiotic
selection to obtain transgenic stem cell clones, footprint-
less gene editing of isogenic iPSC lines has been proven
feasible through TALENs/single-stranded oligonucleo-
tides (ssODNs) without antibiotic selection or FACSort-
ing [13]. This offers not only the opportunity to generate
isogenic control lines by correcting or introducing muta-
tions into the CFTR gene but also to edit potential gen-
omic modifiers of CF disease such as cytokeratin 8,
Syntaxin 1A, or ets homologous factor [32–34]. Import-
antly, this also provides the opportunity to investigate
the isolated effects of rare mutations in cases where no
homozygous donors are available. The second CFTR al-
lele of iPSCs from heterozygous donors or compound
heterozygotes can be fully inactivated through introduc-
tion of sequence-specific deletions or transgene integra-
tions utilizing designer nucleases such as TALENs or
CRISPR/Cas. In the resulting engineered cells, isolated
functional measurement of the remaining allele carrying
the rare mutation of interest is possible.
Genetically engineered reporter iPSCs can finally be differ-
entiated into CF relevant cell types such as respiratory [28],
pancreatic [35], and bile duct epithelium [22] and utilized
for HT screens of small molecules. Also, these iPSC deriva-
tives can be used for the further validation of compound
candidates or combinations of compounds in novel electro-
physiological and cell culture assays that probe more distant
parameters, such as mucus secretion, bioactive lipid metab-
olism, inflammation, and tissue remodeling. Importantly,
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and in contrast to current screening initiatives based on pri-
mary cells or intestinal organoids, the use of CF disease-
specific iPSCs generally offers the unique possibility to valid-
ate promising compounds not only in the cell type used in
the primary screen but also in addition in other organotypic
epithelia (Fig. 1).
Potential hurdles and technical limitations for
application of iPS cells in disease modeling and
drug screening
The impressive progress in the generation and differenti-
ation of iPSCs and in targeted genome engineering clearly
provides manifold new opportunities for disease modeling
and drug screening. In fact, there are already various ex-
amples for the decipherment of pathomechanisms espe-
cially of cardiovascular [36] and neurological disorders
using patient-specific iPSCs [37]. Also, the pharmaceutical
industry has recognized the potential and the advantages
of iPSCs for drug screening and safety pharmacology and
has already made substantial investments in collaborative
efforts with academia and the development of own R&D
units in this evolving field (see, for example, EU’s Innova-
tive Medicines Initiative).
On the other hand, it has to be emphasized that there
are still various technology-related imponderables and
critical hurdles to overcome. One of these hurdles is the
lack of robustness of most differentiation protocols. Even
in case of the most efficient targeted differentiation ap-
proaches that rely on fully defined media and application
of small organic compounds, the success and efficiency is
not always reproducible. Even though it is obvious that
failure of individual preparations is frequently based on
the quality of the starting stem cell population, it is still
barely possible to exclude such failure. Clearly, resulting
variations in the composition and purity of the target cell
population significantly complicate the conduction of high
throughput screens and their routine application in drug
validation and safety pharmacology.
As discussed above, one major advantage of disease
modeling and biological screens based on iPSCs is the
availability of patient-specific cells with defined genetic
background that theoretically allows the direct correlation
of the observed cellular phenotype with clinical data. How-
ever, it is increasingly recognized that individual iPSC
clones generated from one donor can display a high degree
of variation in culture and differentiation characteristics
that can sometimes even exceed phenotypic differences be-
tween iPSC clones of different donors.
Moreover, the experimental requirement for suitable
control lines poses another problem: Because of the well-
known influence of genetic modifiers and the individual
genetic background even in so-called monogenic diseases,
it is meanwhile considered state-of-the-art that isogenic
gene-corrected iPSC lines are used. It is noteworthy, how-
ever, that although the availability of modern genome en-
gineering approaches renders this technically feasible, it is
increasingly recognized that the single cell cloning proce-
dures required to select genetically engineered cells may
result in iPSC clones with properties different from the
original cells.
In general, and although underlying mechanisms are
widely unknown, altered characteristics of individual iPSC
clones are likely due to culture adaptation and selection of
(epi)genetic subclones not only during genetic engineering
but also during iPSC generation, single cell cloning, and
iPSC expansion. At this point, it is still unclear whether such
differences affect only culture and differentiation behavior or
may extend to functional properties of differentiated
Fig. 1 Generation and use of CF-disease-specific iPS cells for drug screening and disease modeling. Adult somatic cells (e.g., from blood)
from any patient can be reprogrammed into induced pluripotent stem (iPS) cells. These cells can be genetically modified, expanded, and
differentiated into the cell types of interest and used (i) to understand the molecular mechanisms underlying disease phenotypes, for
example, the molecular causes for different clinical phenotypes in CF patients with similar mutations, and (ii) in drug screening and
discovery, to determine the effects of candidate drugs and new compounds, and to identify target pathways
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derivatives. Therefore, it remains to be investigated, whether
the use of gene-corrected isogenic control lines is sufficient
to overcome clonal effects on cellular assays designed to
mirror a disease of interest in the dish.
Conclusions
The use of genetically engineered patient-specific iPS
cells can be considered as a highly innovative and valu-
able new platform not only for a better understanding of
the different CF disease phenotypes but also for the
identification of drugs that are able to functionally cor-
rect the organ-specific consequences of the different
classes of common and rare CFTR mutations of wide
clinical applicability.
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